Osama Alsaied Ali

South Valley University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Bassem Ragab Abdel-Aziz

Al-Azhar University

Hazem Ahmed

Future University in Egypt

Mahmoud Ibrahim Almolakab B- Alrashidy

Al-Azhar University

Abdallah Mohammed Ahmed Alsenbawy

Al Azhar University

Ahmed H. Abdellah

Suez Canal University

Cooperative Institutions

Al-Azhar University

Al Azhar University

South Valley University

Assiut University

Al-Azhar University

Future University in Egypt

University of Toronto

Structural Genomics Consortium

Suez Canal University

Al Baha University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Agonist hold Antagonist Protocol versus Antagonist Protocol in Intracytoplasmic Sperm Injection for Infertile Patients with Polycystic Ovary Syndrome

SVU-International Journal of Medical Sciences (2022)

Hazem Ahmed Mahmoud Ibrahim Almolakab B- Alrashidy Osama Alsaied Ali Ahmed H. Abdellah

IntroductionPolycystic Ovary Syndrome (PCOS) is the most common endocrinopathy in reproductive-aged women in the United States, affecting around 7% of women.Although the specific cause of PCOS is unknown, it is assumed to be caused by a complex interplay of hereditary and environmental factors.Changes in luteinizing hormone (LH) action, insulin resistance, and a probable propensity to hyperandrogenism have all been related to the pathophysiology of PCOS (Dafopoulos et al., 2009).The importance of ovarian stimulation in the success of in vitro fertilization and embryo transfer (IVF-ET) treatment has long been recognised.As a result, since the 1980s, a gonadotropin releasing hormone (GnRH) agonist protocol has been created and used in the context of IVF-ET treatment.By desensitising pituitary receptors, the GnRH agonist regimen is aimed to restrict the release of pituitary follicle-stimulating hormone (FSH) and luteinizing hormone (LH) (Huirne et al., 2007).The introduction of a GnRH antagonist regimen, which blocks pituitary receptors, has recently provided another option for ovarian stimulation.The use of a GnRH antagonist strategy has been shown to minimize the length of the ovulatory stimulu sand the occurrence of ovarian hyperstimulation syndrome.The shorter time of analogue medication, the shorter duration of FSH stimulation, and the lesser chance of developing ovarian hyperstimulation syndrome (OHSS) are all advantages of antagonists (Al-Inany et al. ,2016).Because the GnRH antagonist protocol is straightforward, convenient, and flexible, and because it does not cause functional ovarian cysts or "menopausal" symptoms like the agonist protocol, many doctors and patients like it.However, results from randomised clinical trials show that the antagonist protocol retrieves fewer oocytes and has lower pregnancy rates than the agonist long treatment (Kim CH et al., 2011).

10.21608/svuijm.2022.113449.1259

Cite

Citations (0)

Impact of Body Mass Index on Implantation Rate in ICSI Cycles

The Egyptian Journal of Hospital Medicine (2018)

Osama Alsaied Ali Bassem Ragab Abdel-Aziz Abdallah Mohammed Ahmed Alsenbawy

Background: obesity and overweight are recognized as a growing global health problem Worldwide, prevalence of overweight or obesity, defined as an adult body mass index (BMI) of 25 kg m² or greater. Patterns of overweight and obesity differ between countries, regions and by country income, with overweight or obesity more prevalent among men in developed countries and among women in developing countries. Aim of the Work: This study aimed to evaluate the impact of female increased body mass index (BMI) on implantation rate and clinical pregnancy in women undergoing ICSI cycle. Patients and Methods: this is a retrospective study conducted on a total of 400 cycles of assisted reproduction treatment has been evaluated from Orabi IVF Centre and Mit_Ghamr IVF Centre. Data recruited from patient files from January 2016 to July 2018 who did ICSI trial during this period. Patients who included in our study were sub divided into 2 groups according to BMI: 1 st group: normal weight with BMI between 18 and 24.9 kg/m2. (200 case), 2 nd group: overweight and obese women ≥ 25 kg/m2 (200 case). Results: we showed that overweight and obese infertile women had a higher basal serum FSH, LH and estradiol levels than normal weight women. In our study group the duration of infertility was progressively higher as BMI increased. The two groups were comparable regarding female age were not statistically different in both groups. The duration of infertility showed no significant difference between the two groups. As in group (1) it ranges from 10-17 years with median duration of 6 years, while in group (2) it ranges from 0.5-23 with a median duration of 5 years this result a significant difference with p-value (0.057).Conclusion: female overweight and obesity appeared to have deleterious effects on ovarian response to stimulation in women undergoing IVF and implantation rate. Moreover, female obesity compromised IVF outcome.

10.21608/ejhm.2018.20112

Cite

Citations (1)